How fast is the genomics market growing through 2029?

Analysts project the global genomics market will expand from about $46 billion in 2024 to roughly $83 billion by 2029, representing a CAGR near 13%. Growth is fueled by falling sequencing costs, larger biobank datasets, and expanding reimbursement for molecular diagnostics.

What is driving the continued drop in sequencing costs?

Sustained innovation in chemistry, optics, and nanopore physics, combined with higher-throughput instruments and automated sample prep, is pushing costs below the $1,000-per-genome threshold. Economies of scale and improved workflow automation further reduce per-sample labor and compute overhead.

Where is genomics seeing the strongest clinical adoption?

Oncology remains the beachhead, with applications in minimal residual disease detection, targeted therapy selection, and the pursuit of multi-cancer early detection. Population-scale sequencing resources are also accelerating cardiovascular, metabolic, and rare disease insights, enabling risk stratification and earlier intervention.

What infrastructure is needed to manage genomics data at scale?

Cloud-native platforms, containerized workflows, and high-throughput pipelines are essential to process and share multi-petabyte datasets securely. AI-enhanced tools for alignment, variant calling, and annotation reduce turnaround time and improve reproducibility across multi-center studies.

What should leaders watch next in genomics over the next 12–24 months?

Expect wider use of long-read and hybrid sequencing, rising adoption of single-cell and spatial omics, and more real-world evidence linking genetics to outcomes. Policy developments and data interoperability standards will influence collaboration models, while AI will continue to compress time from raw reads to clinical-grade insights.

Genomics Market Trends: Data, Costs, and Clinical Adoption in 2025

Genomics is shifting from research to routine care as sequencing costs plunge and data volumes explode. Market forecasts point to double-digit growth, while cloud and AI reshape pipelines and policy resets recalibrate dealmaking.

Published: November 16, 2025 By Aisha Mohammed Category: Genomics

Genomics Market Trends: Data, Costs, and Clinical Adoption in 2025

A Sector Scaling on Data and Demand

Genomics has moved from a research niche to a core pillar of biomedicine, with investment guided by accelerating data production and clearer clinical use cases. The global genomics market is projected to reach $83.1 billion by 2029 from $46.2 billion in 2024, expanding at a 12.9% CAGR, according to industry analysts at MarketsandMarkets. The growth arc reflects maturing sequencing platforms, richer biobank cohorts, and increasing reimbursement for molecular diagnostics.

Data intensity is rising even faster. Genomics could outpace astronomy and YouTube in raw data generation as whole genomes, single-cell profiles, and spatial maps accumulate at scale, a landmark analysis suggests. Companies such as Illumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies are expanding throughput and automating library prep, effectively turning genomes into a utility input for precision medicine and drug discovery.

Falling Costs, Rising Throughput

Sequencing costs continue their long slide, with the cost to generate a human genome dropping below $1,000 on many platforms; the trend is documented by the U.S. National Human Genome Research Institute’s long-running cost tracking series, NHGRI data show. As capital and reagent efficiency improve, labs are pushing beyond short-read coverage into long-read and hybrid strategies to resolve structural variants and complex regions at scale.

That shift is reshaping platform mixes and pipeline design. Oxford Nanopore’s PromethION line and Illumina’s latest high-throughput instruments anchor competing roadmaps, while Thermo Fisher’s clinical testing footprint supports targeted panels in regulated settings. Startups including DNAnexus and Tempus are building data fabrics atop this hardware layer to standardize pipelines across research and clinical environments. This builds on broader Genomics trends as labs consolidate around interoperable, audit-ready workflows.

From Bench to Bedside: Clinical Adoption and Real-World Evidence

Population-scale genomics is now delivering real-world evidence with clinical utility. The UK Biobank recently completed whole-genome sequencing for its 500,000 participants, unlocking a treasure trove for gene discovery and risk prediction, according to the program...

Read the full article at AI BUSINESS 2.0 NEWS